Silence Therapeutics PLC
SLN5.950USD
-0.220-3.57%
Handelsschluss 08/04, 16:00（ET）Kurse um 15 Minuten verzögert
843.06MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Silence Therapeutics PLC Unternehmen
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.
Unternehmensinformationen
BörsenkürzelSLN
Name des UnternehmensSilence Therapeutics PLC
IPO-datumJan 05, 2010
CEOMr. Craig A. Tooman
Anzahl der mitarbeiter116
WertpapierartDepository Receipt
GeschäftsjahresendeJan 05
Addresse72 Hammersmith Road
StadtLONDON
BörseNASDAQ Global Market Consolidated
LandUnited Kingdom
PostleitzahlW14 8TH
Telefon442034576900
Websitehttps://www.silence-therapeutics.com/
BörsenkürzelSLN
IPO-datumJan 05, 2010
CEOMr. Craig A. Tooman
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United Kingdom
43.11M
99.67%
Germany
144.00K
0.33%
USA
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Griffiths (Richard Ian)
24.38%
TCG Crossover Management, LLC
6.42%
Invus Public Equities Advisors, LLC
5.91%
Redmile Group, LLC
4.69%
Morgan Stanley & Co. LLC
4.01%
Other
54.59%
Aktionäre
Aktionäre
Anteil
Griffiths (Richard Ian)
24.38%
TCG Crossover Management, LLC
6.42%
Invus Public Equities Advisors, LLC
5.91%
Redmile Group, LLC
4.69%
Morgan Stanley & Co. LLC
4.01%
Other
54.59%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
24.38%
Investment Advisor
18.47%
Investment Advisor/Hedge Fund
10.53%
Hedge Fund
7.10%
Research Firm
5.08%
Venture Capital
3.35%
Private Equity
2.43%
Other
28.65%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
130
33.69M
71.34%
-14.09M
2025Q1
133
31.94M
67.63%
-14.00M
2024Q4
128
31.43M
66.56%
-10.23M
2024Q3
111
35.93M
77.05%
-5.19M
2024Q2
96
34.94M
74.95%
-4.57M
2024Q1
86
35.43M
76.18%
+4.14M
2023Q4
61
30.21M
78.15%
-609.51K
2023Q3
58
32.62M
88.08%
+1.55M
2023Q2
54
31.78M
89.08%
+2.79M
2023Q1
52
31.17M
88.54%
+2.74M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Griffiths (Richard Ian)
11.51M
24.38%
+543.58K
+4.95%
Jun 25, 2025
TCG Crossover Management, LLC
3.03M
6.42%
--
--
Mar 31, 2025
Invus Public Equities Advisors, LLC
2.79M
5.91%
-41.94K
-1.48%
Mar 31, 2025
Redmile Group, LLC
2.21M
4.69%
-184.37K
-7.68%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.90M
4.01%
+333.48K
+21.34%
Mar 31, 2025
Lombard Odier Asset Management (USA) Corp.
1.85M
3.92%
-6.29K
-0.34%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
1.15M
2.43%
--
--
Mar 31, 2025
Vivo Capital, LLC
1.11M
2.34%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
1.04M
2.21%
-7.25K
-0.69%
Mar 31, 2025
Nextech Invest, Ltd.
952.40K
2.02%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.01%
SPDR S&P International Small Cap ETF
0.01%
ActivePassive International Equity ETF
0%
Tema Heart & Health ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.93%
ProShares Ultra Nasdaq Biotechnology
Anteil0.03%
Invesco Nasdaq Biotechnology ETF
Anteil0.03%
iShares Biotechnology ETF
Anteil0.01%
SPDR S&P International Small Cap ETF
Anteil0.01%
ActivePassive International Equity ETF
Anteil0%
Tema Heart & Health ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
